Dalia El Arawi started her LAI journey during COVID19 lockdown on the physical and computational aided design of bispecific antibodies for cancer immunotherapy under the supervision of Laurent Limozin. Her main objective will consist of testing bispecific antibodies using in vitro Antibody Dependent Cell Cytotoxicity mediated by NK cells employing TIRFM and RICM.